ALLK - Allakos Inc.
IEX Last Trade
1.25
-0.015 -1.200%
Share volume: 3,445
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.26
-0.02
-1.19%
Fundamental analysis
15%
Profitability
0%
Dept financing
1%
Liquidity
50%
Performance
25%
Performance
5 Days
-1.55%
1 Month
42.03%
3 Months
120.68%
6 Months
19.81%
1 Year
-53.48%
2 Year
-83.00%
Key data
Stock price
$1.25
DAY RANGE
$1.24 - $1.28
52 WEEK RANGE
$0.56 - $3.36
52 WEEK CHANGE
-$53.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Robert Alexander
Region: US
Website: allakos.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: allakos.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
Recent news